

# Halil Gen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2504353/halil-genc-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

690  
citations

14  
h-index

26  
g-index

30  
ext. papers

765  
ext. citations

3.3  
avg, IF

2.92  
L-index

#	Paper	IF	Citations
29	Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. <i>Diabetes Research and Clinical Practice</i> , <b>2007</b> , 76, 24-9	7.4	149
28	Plasma apelin and ADMA Levels in patients with essential hypertension. <i>Clinical and Experimental Hypertension</i> , <b>2010</b> , 32, 179-83	2.2	72
27	Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 380-387	3.1	64
26	Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. <i>Clinical Endocrinology</i> , <b>2013</b> , 78, 712-7	3.4	59
25	The relationship of serum uric acid with non-alcoholic fatty liver disease. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 383-8	3.5	53
24	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , <b>2015</b> , 9, 576-82	4.9	42
23	LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. <i>Atherosclerosis</i> , <b>2009</b> , 204, 222-8	3.1	42
22	Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. <i>Uppsala Journal of Medical Sciences</i> , <b>2010</b> , 115, 253-9	2.8	34
21	Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 96, 47-52	7.4	26
20	Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. <i>Endocrine</i> , <b>2010</b> , 37, 455-9	4	25
19	Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , <b>2015</b> , 13, 319-25	2.6	20
18	Choroidal Thickness Changes in the Acute Attack Period in Patients with Familial Mediterranean Fever. <i>Ophthalmologica</i> , <b>2016</b> , 235, 72-7	3.7	17
17	Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 1144-8	2.2	16
16	The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Saudi Journal of Gastroenterology</i> , <b>2015</b> , 21, 139-45	3	16
15	Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 1355-61	2.4	12
14	Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: the impact of metabolic syndrome. <i>Clinical Biochemistry</i> , <b>2012</b> , 45, 92-5	3.5	11
13	Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate <i>Helicobacter pylori</i> in a Turkish population. <i>Helicobacter</i> , <b>2012</b> , 17, 486-90	4.9	7

12	Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2010</b> , 70, 399-403	2	7
11	The relationship between blood urea nitrogen levels and metabolic, biochemical, and histopathologic findings of nondiabetic, nonhypertensive patients with nonalcoholic fatty liver disease. <i>Turkish Journal of Medical Sciences</i> , <b>2016</b> , 46, 985-91	2.7	4
10	Carotid atherosclerosis or nonalcoholic fatty liver disease: which comes first?. <i>Atherosclerosis</i> , <b>2013</b> , 231, 187-8	3.1	3
9	Non-alcoholic fatty liver disease per se is not associated with carotid atherosclerosis. <i>Gulhane Medical Journal</i> , <b>2013</b> , 55, 84		3
8	Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 1000-1; author reply 1001-2	2.4	3
7	C reactive protein levels in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 507-8; author reply 508-10	13.4	2
6	The presence of MEFV gene mutations in patients with primary osteoarthritis who require surgery. <i>Korean Journal of Internal Medicine</i> , <b>2013</b> , 28, 594-8	2.5	2
5	Platelet aggregation is not enhanced in patients with prediabetes. <i>Upsala Journal of Medical Sciences</i> , <b>2007</b> , 112, 338-46	2.8	1
4	Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose. <i>Mediators of Inflammation</i> , <b>2006</b> , 2006, 32508	4.3	0
3	Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 498-9; author reply 499-500	13.4	
2	Microalbuminuria and nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, E5; author reply E6	12.7	
1	Transforming growth factor [TGF- $\beta$ ] levels in otherwise healthy subjects with impaired glucose tolerance. <i>Endokrynologia Polska</i> , <b>2010</b> , 61, 691-4	1.1	